GEHC — GE HealthCare Technologies Inc.

GE Healthcare Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $5.3 billion, representing 3.5% organic growth year-over-year.
• Adjusted EBIT: $750 million, with an adjusted EBIT margin of 14.2%, down 40 basis points year-over-year.
• Adjusted EPS: $1.13, up 6.6% year-over-year, benefiting from tariff refunds and a lower tax rate.
• Free Cash Flow: $68 million, influenced by $107 million in tariff refunds.
• Orders Growth: 11.1% year-over-year, with a book-to-bill ratio of 1.15x and a record backlog of $23.9 billion, up $2.6 billion year-over-year.

2. Strategic Updates and Business Highlights

• Product Launches: Continued success in launching AI-enabled products, including advancements in CT and ultrasound technologies.
• Patient Care Solutions (PCS): Strong order growth in monitoring and anesthesia products, despite revenue challenges due to operational fulfillment issues.
• Pharmaceutical Diagnostics (PDx): Achieved 14.6% organic revenue growth, driven by robust demand for contrast media and radiopharmaceuticals.
• Heartbeat System: Implementation of the Heartbeat operating system is enhancing commercial execution and aligning product development with customer needs.

3. Forward Guidance and Outlook

• Full-Year Guidance: Maintaining organic sales growth of 3% to 4% and adjusted EBIT margin expansion of 10 to 40 basis points, targeting a range of 15.4% to 15.7%.
• Adjusted EPS Guidance: Expected to remain in the range of $4.80 to $5.00.
• Medium-Term Targets: Confident in achieving $500 million or more in annual revenues from PDx by 2028, with a focus on innovation and operational efficiency.

4. Bad News, Challenges, or Points of Concern

• Patient Care Solutions (PCS): Revenue declined 13.5% due to operational fulfillment challenges, impacting overall EBIT margins.
• Inflationary Pressures: Continued inflation in memory chips, oil, and freight costs is a headwind, although mitigation strategies are being implemented.
• Transition in CFO: Jay Saccaro announced his departure, raising concerns about continuity during this leadership change.

5. Notable Q&A Insights

• Sustainability of Orders Growth: CEO Peter Arduini emphasized that the 11% orders growth was broad-based and not driven by one-time events, indicating confidence in continued demand.
• PCS Stabilization: Arduini highlighted that while PCS faced challenges, there is a strong focus on improving fulfillment and operational efficiency, with expectations for recovery in the second half of the year.
• Market Dynamics in China: Arduini noted ongoing changes in China’s pricing and budget environment but confirmed that performance there is in line with expectations.
• Impact of New Products: The Photonova Spectra CT platform is expected to drive future growth, although its current contribution to orders is minimal.

This summary encapsulates GE Healthcare's performance and strategic direction for Q2 2026, highlighting both achievements and challenges faced in the current market landscape.